New Study for Individuals with Early Parkinson’s

The Parkinson’s Disease and Movement Disorders Center at Boston University Medical Campus will be conducting a new clinical medication study for individuals with early Parkinson’s.

The SPARK study is evaluating an investigational drug that targets alpha-synuclein (α-syn), a molecule associated with Parkinson’s disease, to see if it may potentially help to slow or reduce progression in the earliest stages of the disease. If you have been diagnosed within the past three years, are between 40 and 80 years of age (inclusive), and have not received levodopa to manage symptoms, you may be eligible to participate.

Contact Raymond James for more information about this study at (617) 638-7745.

Click here for a flyer.

Directory|BUMC
March 14, 2018
Primary teaching affiliate
of BU School of Medicine